07
Dez
2015
Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients
Ort:
Orlando, FL, USA
(7th Annual Meeting of the American Society of Hematology, Session 623 (Lymphoma): Chemotherapy, excluding Pre-Clinical Models: DLBCL – Beyond R-CHOP, Orange County Convention Center, Tangerine 3,5)
Details